Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. More Details
Moderate growth potential with imperfect balance sheet.
Share Price & News
How has Ligand Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: LGND is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: LGND's weekly volatility (12%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: LGND exceeded the US Biotechs industry which returned 31.3% over the past year.
Return vs Market: LGND exceeded the US Market which returned 55.3% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Ligand Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StDid You Miss Ligand Pharmaceuticals' (NASDAQ:LGND) Impressive 109% Share Price Gain?
1 month ago | Simply Wall StAre Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Investors Paying Above The Intrinsic Value?
Is Ligand Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: LGND ($153.44) is trading above our estimate of fair value ($114.93)
Significantly Below Fair Value: LGND is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: LGND is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: LGND is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate LGND's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: LGND is good value based on its PB Ratio (3.5x) compared to the US Biotechs industry average (3.9x).
How is Ligand Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LGND is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: LGND is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: LGND's is expected to become profitable in the next 3 years.
Revenue vs Market: LGND's revenue (6.3% per year) is forecast to grow slower than the US market (9.9% per year).
High Growth Revenue: LGND's revenue (6.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if LGND's Return on Equity is forecast to be high in 3 years time
How has Ligand Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: LGND is currently unprofitable.
Growing Profit Margin: LGND is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: LGND is unprofitable, but has reduced losses over the past 5 years at a rate of 14.1% per year.
Accelerating Growth: Unable to compare LGND's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LGND is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.3%).
Return on Equity
High ROE: LGND has a negative Return on Equity (-0.42%), as it is currently unprofitable.
How is Ligand Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: LGND's short term assets ($500.6M) exceed its short term liabilities ($100.1M).
Long Term Liabilities: LGND's short term assets ($500.6M) do not cover its long term liabilities ($552.6M).
Debt to Equity History and Analysis
Debt Level: LGND's debt to equity ratio (62.3%) is considered high.
Reducing Debt: LGND's debt to equity ratio has reduced from 72.5% to 62.3% over the past 5 years.
Debt Coverage: LGND's debt is not well covered by operating cash flow (12.3%).
Interest Coverage: LGND is unprofitable, therefore interest payments are not well covered by earnings.
What is Ligand Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate LGND's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate LGND's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if LGND's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if LGND's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of LGND's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
John Higgins (50 yo)
Mr. John L. Higgins has been the President and Chief Executive Officer of Ligand Pharmaceuticals Incorporated since January 16, 2007. Mr. Higgins serves as the President and Chief Executive Officer of Moon...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD6.77M) is above average for companies of similar size in the US market ($USD5.05M).
Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.
Experienced Management: LGND's management team is seasoned and experienced (6.3 years average tenure).
Experienced Board: LGND's board of directors are seasoned and experienced ( 12.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: LGND insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Ligand Pharmaceuticals Incorporated's company bio, employee growth, exchange listings and data sources
- Name: Ligand Pharmaceuticals Incorporated
- Ticker: LGND
- Exchange: NasdaqGM
- Founded: 1987
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$2.549b
- Shares outstanding: 16.61m
- Website: https://www.ligand.com
Number of Employees
- Ligand Pharmaceuticals Incorporated
- 3911 Sorrento Valley Boulevard
- Suite 110
- San Diego
- United States
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/04/10 22:05|
|End of Day Share Price||2021/04/09 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.